About Alamar Biosciences
Alamar Biosciences is a company based in Fremont (United States) founded in 2018 by Steve Chen and Yuling Luo. Alamar Biosciences has raised $230 million across 4 funding rounds from investors including HHS, Qiming Venture Partners and Sands Capital. Alamar Biosciences offers products and services including NULISA Platform, ARGO HT System, NULISA Assays for Immunology, NULISA Assays for Neurology, and NULISA Assays for Oncology. Alamar Biosciences operates in a competitive market with competitors including Sequenta, Glympse Bio, Crescendo Bioscience, Harmonic Discovery and Seahorse Bioscience, among others.
- Headquarter Fremont, United States
- Founders Steve Chen, Yuling Luo
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alamar Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$230 M (USD)
in 4 rounds
-
Latest Funding Round
$50 M (USD), Series C
Jan 12, 2026
-
Investors
HHS
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alamar Biosciences
Alamar Biosciences offers a comprehensive portfolio of products and services, including NULISA Platform, ARGO HT System, NULISA Assays for Immunology, NULISA Assays for Neurology, and NULISA Assays for Oncology.
Enables sensitive detection of protein biomarkers in fluid samples.
Automates proteomics analysis for efficient biomarker research.
Facilitates profiling of immunological protein biomarkers accurately.
Supports detection of neurological biomarkers for disease studies.
Aids in analyzing oncological protein biomarkers for research.
People of Alamar Biosciences
Unlock access to complete
Funding Insights of Alamar Biosciences
Alamar Biosciences has successfully raised a total of $230M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alamar Biosciences
Alamar Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Qiming Venture Partners and Sands Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked |
Investor details for Alamar Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alamar Biosciences
Investment portfolio details for Alamar Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alamar Biosciences
Detailed financials for Alamar Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alamar Biosciences Comparisons
Peer comparison for Alamar Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alamar Biosciences
Alamar Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sequenta, Glympse Bio, Crescendo Bioscience, Harmonic Discovery and Seahorse Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
|
| Locked | Locked | Locked |
Multiple human diseases are monitored noninvasively through urine-based analysis.
|
|
| Locked | Locked | Locked |
Molecular tests for autoimmune and inflammatory diseases are provided.
|
|
| Locked | Locked | Locked |
Developer of kinase inhibitor drugs for oncology
|
|
| Locked | Locked | Locked |
Cellular metabolic status is measured via the Seahorse XFp Analyzer.
|
Detailed competitors of Alamar Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alamar Biosciences
Complete news archive for Alamar Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alamar Biosciences
Alamar Biosciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Alamar Biosciences is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
Yuling Luo is the current CEO of Alamar Biosciences. They have also founded this company.
Alamar Biosciences is a funded company, having raised a total of $230M across 4 funding rounds to date.
Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. The companys proprietary NULISA Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. Applications include clinical assay development, biomarker discovery and validation, and drug development.
Alamar Biosciences's top competitors include Sequenta, Glympse Bio and Harmonic Discovery.
Alamar Biosciences offers NULISA Platform, ARGO HT System, NULISA Assays for Immunology, NULISA Assays for Neurology, and NULISA Assays for Oncology.
Alamar Biosciences has 9 investors. Key investors include HHS, Qiming Venture Partners, Sands Capital, Sherpa Healthcare Partners, and Morningside.